Despite Wall Street analysts defending Biohaven Pharmaceutical Holding Co Ltd. (BHVN.US) in response to its Christmas Eve announcement, the biotech firm's stock still tumbled nearly 13% in pre-market trading on Friday. This sharp decline followed the failure of a Phase II clinical trial for its antidepressant candidate, BHV-7000. The New Haven, Connecticut-based company stated on Wednesday that it would discontinue clinical development of all psychiatric candidates in its portfolio following a restructuring decision. This move came after BHV-7000 (opakalim) failed to meet the primary endpoint in a Phase II proof-of-concept study for major depressive disorder.

Citi analyst Samantha Semenkow maintained a "Buy" rating on Biohaven. She argued that while the depression trial data for BHV-7000 was disappointing, investor expectations for the study's success were "extremely low" to begin with. Myles Minter of William Blair expressed a similar sentiment. He noted that although the trial's failure to hit its endpoint was disappointing, his firm rates Biohaven "Market Perform," citing "increased clinical trial execution difficulty and a heightened placebo effect in recent years."

In the wake of this clinical setback, Biohaven is shifting its focus to the first half of 2026. During this period, the company is scheduled to report topline results from one of two key studies evaluating the efficacy of 25mg and 50mg doses of opakalim (BHV-7000) in patients with treatment-resistant focal epilepsy. Citi analyst Semenkow pointed out that investors are currently more focused on the later-stage study data for BHV-7000 in the epilepsy indication, with this critical data expected in the first half of 2026.

Raymond James analyst Christopher Raymond holds a comparable view, advising investors to "continue focusing on the potential opportunity in focal epilepsy." Leerink analyst Marc Goodman acknowledged in a report that the disappointing trial data was "not unexpected." Goodman reaffirmed his "Outperform" rating on Biohaven, emphasizing that this data release is one of several key catalysts the company is counting on to drive share price appreciation over the next 6 to 9 months.

Concurrently, RBC Capital Markets analyst Leonid Timashev assigned an "Sector Perform" rating. He suggested the current setback might be a one-time event, characterizing it essentially as a clearing of the decks that "removes an overhang" and paves the way for a higher-probability catalyst event in 2026.